Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 18, 2008

View Archived Issues

Amyloid-beta protein dimers identified as cause of synapse impairment

Cara's peripherally active kappa opioid receptor agonist may be useful in treating visceral pain

New antidiabetic compounds described in recent patents

Effective antinociception without reward by novel endomorphin-1 analogue

VAP-1 ligands for diagnosing inflammatory disorders claimed in recent patent

Novel compounds with potential in the treatment of cancer disclosed

Mu opiod receptor agonist AS-006 effective in rat model of osteoarthritic pain

DiaMedica initiates enrollment in phase IIa clinical trial for DM-99 in type 2 diabetes

FDA approves Gen-Probe's supplemental regulatory application for Procleix Ultrio in HBV

SymBio and Eisai sign license agreement for bendamustine hydrochloride in Japan

Spectrum launches Fusilev injection and files amendment to NDA for tablet formulation

CV Therapeutics receives EMEA approval for Ranexa brand name

Abbott and AstraZeneca enter nonexclusive U.S. marketing agreement for Crestor

GTC and Ovation close agreement to develop and market ATryn in U.S

Nutra Pharma reports safety data from phase IIb/IIIa clinical study of RPI-78M in AMN

P-selectin inhibitor PSI-421 shows efficacy in models of vascular injury

Antisoma reports survival data from phase II study of ASA-404 in prostate cancer

FDA grants orphan drug designation to Santhera's omigapil in congenital muscular dystrophy

OrthoLogic completes dosing for phase Ib human clinical trial of AZX-100 in scarring

Seikagaku to initiate Japanese phase I clinical trial of CF-101 in rheumatoid arthritis

FDA approves Prestwick's Xenazine for chorea associated with Huntington's disease

Isis initiates phase I study of ISIS-353512 in healthy volunteers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...